2022 Fiscal Year Final Research Report
Research for practical and quantitative analysis methods of DNA damage base as a cancer risk index and for acquisition of innovative sensitivity of them
Project/Area Number |
20K05569
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 34020:Analytical chemistry-related
|
Research Institution | Gifu Pharmaceutical University |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Keywords | DNA損傷 / RNA損傷 / 発がんリスクマーカー / LC/MS/MS / CE濃縮—ナノESI-MS / グリオーマ / テモゾロミド / 飲酒 |
Outline of Final Research Achievements |
We have developed a method for analyzing nucleic acid damaged bases as carcinogenic risk markers. Along with the development of a highly practical method using LC/MS/MS, we have also succeeded in developing an ultra-sensitive analytical method that combines high-magnification concentration within a microvolume in a capillary electrophoresis field with a nano-ESI-MS system. Studies for applying them to practical analysis applications were carried out mainly using human-derived cultured cells. In addition, we studied the application of damage analysis as an index for enhancing the therapeutic effect of alkylating anticancer drugs and obtained useful knowledge.
|
Free Research Field |
分析化学
|
Academic Significance and Societal Importance of the Research Achievements |
長寿社会になった先進国、特に日本では、健康寿命を延ばすことが社会保険費の削減に極めて効果的であり、喫緊の課題になっている。本研究は、老いの本質の一つと言えるDNA,RNAの損傷の蓄積状況を、量と内容から分析するための方法論の開発をおこなったものであり、この計画の遂行の結果、実用的な方法と極めて高感度な方法が開発された。本研究の成果は、検診での損傷体分析の実現を近づけるものである。加えて、本法は、日本人の半分が罹患するがんの薬物治療効果を高めるための薬効のバロメーターとして損傷体を分析することにも役立つ方法にもなった。
|